Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
T-cell receptors (TCRs) recognizing F1- and V-derived peptides presented on MHC class II are specialized immune receptors that play a pivotal role in the defense against Yersinia pestis, the causative agent of plague [1]. The F1 (Caf1) and V (LcrV) antigens are critical virulence factors; F1 forms a protective capsule, while V is essential for the injection of effector proteins into host cells via the type III secretion system [2]. These TCRs are expressed on the surface of CD4+ T lymphocytes and are responsible for identifying specific bacterial peptide fragments displayed by Major Histocompatibility Complex (MHC) class II molecules on antigen-presenting cells [3]. Upon recognition, the TCR initiates a signaling cascade that leads to T-cell activation, proliferation, and the secretion of pro-inflammatory cytokines like interferon-gamma (IFN-γ), which are necessary for activating macrophages to kill the intracellular bacteria [4]. Because of their central role in protective immunity, these TCR-peptide-MHC interactions are the primary focus of subunit vaccine development, such as the rF1-V fusion protein vaccine, which aims to elicit a robust and memory-capable T-cell response [5]. A significant challenge in targeting these receptors is the high degree of MHC polymorphism in human populations, which can lead to variable recognition of specific F1 and V epitopes across different individuals [6].
Vaccines containing F1 and V antigens prime the immune system to generate a population of CD4+ T cells expressing these specific TCRs; upon subsequent infection, these TCRs recognize the peptide-MHC II complexes on antigen-presenting cells, triggering a rapid Th1-mediated immune response and macrophage activation to clear Yersinia pestis.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T-cell receptor recognizing Yersinia pestis F1 and V antigens (F1/V-specific TCR).